Search results for "Main Protease"

showing 5 items of 5 documents

In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors

2020

Coronavirus Disease 2019 (COVID-19) is an infectious illness caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), originally identified in Wuhan, China (December 2019) and has since expanded into a pandemic. Here, we investigate metabolites present in several common spices as possible inhibitors of COVID-19. Specifically, 32 compounds isolated from 14 cooking seasonings were examined as inhibitors for SARS-CoV-2 main protease (Mpro), which is required for viral multiplication. Using a drug discovery approach to identify possible antiviral leads, in silico molecular docking studies were performed. Docking calculations revealed a high potency of salvianolic acid A and curcu…

0301 basic medicineCurcuminIn silicomedicine.medical_treatmentPneumonia ViralHealth InformaticsMolecular dynamicsMolecular Dynamics SimulationViral Nonstructural ProteinsArticleSARS-CoV-2 main proteaseBetacoronavirus03 medical and health scienceschemistry.chemical_compoundCaffeic Acids0302 clinical medicineDrug DiscoverymedicineHumansProtease InhibitorsSpicesPandemicsCoronavirus 3C Proteaseschemistry.chemical_classificationNatural productProteaseSARS-CoV-2Secondary metabolitesCOVID-19LopinavirAmino acidComputer Science ApplicationsMolecular Docking SimulationCysteine Endopeptidases030104 developmental biologyEnzymechemistryBiochemistryDocking (molecular)Molecular dockingLactatesCurcuminThermodynamicsCoronavirus Infections030217 neurology & neurosurgerymedicine.drugComputers in Biology and Medicine
researchProduct

The dimer-monomer equilibrium of SARS-CoV-2 main protease is affected by small molecule inhibitors

2021

AbstractThe maturation of coronavirus SARS-CoV-2, which is the etiological agent at the origin of the COVID-19 pandemic, requires a main protease Mpro to cleave the virus-encoded polyproteins. Despite a wealth of experimental information already available, there is wide disagreement about the Mpro monomer-dimer equilibrium dissociation constant. Since the functional unit of Mpro is a homodimer, the detailed knowledge of the thermodynamics of this equilibrium is a key piece of information for possible therapeutic intervention, with small molecules interfering with dimerization being potential broad-spectrum antiviral drug leads. In the present study, we exploit Small Angle X-ray Scattering (…

0301 basic medicineMolecular biologyProtein ConformationSciencemedicine.medical_treatmentDimerBiophysicsPlasma protein binding010402 general chemistryAntiviral Agents01 natural sciencesArticleDissociation (chemistry)03 medical and health scienceschemistry.chemical_compoundProtein structureX-Ray DiffractionDrug DiscoverymedicineHumansProtease InhibitorsCoronavirus 3C ProteasesVirtual screeningMultidisciplinaryProteaseSARS-CoV-2ChemistryQSARS-CoV-2 main protease Mpro enzymatic activity inhibition Small Angle X-ray Scattering small inhibitors virtual screeningRCOVID-19Computational BiologySmall moleculeComputational biology and bioinformatics0104 chemical sciencesMolecular Docking SimulationDissociation constant030104 developmental biologyBiophysicsMedicineThermodynamicsDimerizationProtein Binding
researchProduct

In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection

2020

COVID-19 is a pandemic health emergency faced by the entire world. The clinical treatment of the severe acute respiratory syndrome (SARS) CoV-2 is currently based on the experimental administration of HIV antiviral drugs, such as lopinavir, ritonavir, and remdesivir (a nucleotide analogue used for Ebola infection). This work proposes a repurposing process using a database containing approximately 8000 known drugs in synergy structure- and ligand-based studies by means of the molecular docking and descriptor-based protocol. The proposed in silico findings identified new potential SARS CoV-2 main protease (MPRO) inhibitors that fit in the catalytic binding site of SARS CoV-2 MPRO. Several sel…

Models Molecular0301 basic medicineAgingmedicine.medical_treatmentcoronaviruslcsh:QR1-502Viral Nonstructural Proteinsmedicine.disease_causelcsh:Microbiology0302 clinical medicineSettore BIO/10 - BiochimicaCoronavirus 3C ProteasesCoronavirusvirus diseasesLopinavirHypothesisMolecular Docking SimulationCysteine EndopeptidasesDrug repositioningInfectious Diseases030220 oncology & carcinogenesisCoronavirus InfectionsOxidation-Reductionmedicine.drugDNA damageIn silicoPneumonia ViralBiologyAntiviral AgentsHIV-proteaseBetacoronavirus03 medical and health sciencesSARS-CoV-2 main proteaseVirologymedicineHumansComputer SimulationProtease InhibitorsPandemicsBinding SitesProteaseSARS-CoV-2Drug RepositioningCOVID-19HIV Protease InhibitorsDRUDIT web servicemolecular dockingNADbiology.organism_classificationVirologySettore CHIM/08 - Chimica FarmaceuticaCOVID-19 Drug Treatmentcoronaviru030104 developmental biologyNADHRitonavirBetacoronavirusDNA Damage
researchProduct

Enteroviruses and coronaviruses: similarities and therapeutic targets

2021

ABSTRACT Introduction: Enteroviruses are common viruses causing a huge number of acute and chronic infections and producing towering economic costs. Similarly, coronaviruses cause seasonal mild infections, epidemics, and even pandemics and can lead to severe respiratory symptoms. It is important to develop broadly acting antiviral molecules to efficiently tackle the infections caused by thes. Areas covered: This review illuminates the differences and similarities between enteroviruses and coronaviruses and examines the most appealing therapeutic targets to combat both virus groups. Publications of both virus groups and deposited structures discovered through PubMed to March 2021 for viral p…

ProteasesPolyproteinsvirusesmedicine.medical_treatmentClinical BiochemistrycoronavirusReviewSARS-COV-2Biologymedicine.disease_causeAntiviral Agents3C proteaseVirusSubstrate Specificity03 medical and health sciencesDrug DiscoveryPandemicmedicineAnimalsHumansVirus classificationEnterovirus030304 developmental biologyCoronavirusPharmacology0303 health sciencesProtease030306 microbiologyCOVID-19Virology3. Good healthCysteine Endopeptidasesmain proteaseMolecular MedicineEnterovirusResearch ArticleExpert Opinion on Therapeutic Targets
researchProduct

Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure-Activity Relationship Insights and Evolution Perspectives

2022

The viral main protease is one of the most attractive targets among all key enzymes involved in the SARS-CoV-2 life cycle. Covalent inhibition of the cysteine145 of SARS-CoV-2 MPRO with selective antiviral drugs will arrest the replication process of the virus without affecting human catalytic pathways. In this Perspective, we analyzed the in silico, in vitro, and in vivo data of the most representative examples of covalent SARS-CoV-2 MPRO inhibitors reported in the literature to date. In particular, the studied molecules were classified into eight different categories according to their reactive electrophilic warheads, highlighting the differences between their reversible/irreversible mech…

SARS-CoV-2COVID-19Viral Nonstructural ProteinsAntiviral AgentsSettore CHIM/08 - Chimica FarmaceuticaCOVID-19 Drug TreatmentCovalent inhibitorsMolecular Docking SimulationCysteine EndopeptidasesStructure-Activity RelationshipMain ProteaseDrug DiscoveryMolecular MedicineHumansProtease InhibitorsCysteineCoronavirus 3C Proteases
researchProduct